FR24C1008I1 - Anticorps dirigés contre l'inhibiteur de la voie du facteur tissulaire - Google Patents

Anticorps dirigés contre l'inhibiteur de la voie du facteur tissulaire

Info

Publication number
FR24C1008I1
FR24C1008I1 FR24C1008C FR24C1008C FR24C1008I1 FR 24C1008 I1 FR24C1008 I1 FR 24C1008I1 FR 24C1008 C FR24C1008 C FR 24C1008C FR 24C1008 C FR24C1008 C FR 24C1008C FR 24C1008 I1 FR24C1008 I1 FR 24C1008I1
Authority
FR
France
Prior art keywords
antibodies against
tissue factor
pathway inhibitor
against tissue
factor pathway
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR24C1008C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40639722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR24C1008(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of FR24C1008I1 publication Critical patent/FR24C1008I1/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR24C1008C 2008-12-22 2024-02-26 Anticorps dirigés contre l'inhibiteur de la voie du facteur tissulaire Active FR24C1008I1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08172520 2008-12-22
PCT/EP2009/067598 WO2010072691A1 (fr) 2008-12-22 2009-12-18 Anticorps dirigés contre l'inhibiteur de la voie du facteur tissulaire
EP09793543.1A EP2379600B2 (fr) 2008-12-22 2009-12-18 Anticorps dirigés contre l'inhibiteur de la voie du facteur tissulaire

Publications (1)

Publication Number Publication Date
FR24C1008I1 true FR24C1008I1 (fr) 2024-04-19

Family

ID=40639722

Family Applications (1)

Application Number Title Priority Date Filing Date
FR24C1008C Active FR24C1008I1 (fr) 2008-12-22 2024-02-26 Anticorps dirigés contre l'inhibiteur de la voie du facteur tissulaire

Country Status (19)

Country Link
US (5) US8361469B2 (fr)
EP (3) EP3260466A1 (fr)
JP (2) JP5714505B2 (fr)
KR (2) KR101745394B1 (fr)
CN (1) CN102325795B (fr)
AU (1) AU2009331570C1 (fr)
BR (1) BRPI0924058B1 (fr)
CA (1) CA2745317C (fr)
DK (1) DK2379600T4 (fr)
ES (1) ES2458665T5 (fr)
FR (1) FR24C1008I1 (fr)
IL (1) IL213356A (fr)
MX (1) MX2011006501A (fr)
PL (1) PL2379600T5 (fr)
PT (1) PT2379600E (fr)
RU (1) RU2562114C2 (fr)
TW (1) TWI476003B (fr)
WO (1) WO2010072691A1 (fr)
ZA (1) ZA201104599B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8287861B2 (en) 2008-06-30 2012-10-16 Novo Nordisk A/S Anti-human interleukin-20 antibodies
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
RU2562114C2 (ru) 2008-12-22 2015-09-10 Ново Нордиск А/С Антитела против ингибитора метаболического пути тканевого фактора
US8454956B2 (en) 2009-08-31 2013-06-04 National Cheng Kung University Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
CN107496917B (zh) * 2010-02-26 2021-06-11 诺沃—诺迪斯克有限公司 包含稳定抗体的组合物
KR101903931B1 (ko) 2010-03-01 2018-10-02 바이엘 헬스케어 엘엘씨 조직 인자 경로 억제제 (ｔｆｐｉ)에 대한 최적화된 모노클로날 항체
WO2011147921A1 (fr) 2010-05-28 2011-12-01 Novo Nordisk A/S Compositions stables multi-doses comprenant un anticorps et un agent conservateur
US9228022B2 (en) 2010-06-30 2016-01-05 Novo Nordisk A/S Antibodies that are capable of specifically binding tissue factor pathway inhibitor
TW201212938A (en) 2010-06-30 2012-04-01 Novo Nordisk As Antibodies that are capable of specifically binding tissue factor pathway inhibitor
ES2722824T3 (es) * 2011-04-01 2019-08-19 Bayer Healthcare Llc Anticuerpos monoclonales contra el inhibidor de la ruta del factor tisular (TFPI)
US9221904B2 (en) 2012-07-19 2015-12-29 National Cheng Kung University Treatment of osteoarthritis using IL-20 antagonists
US8852588B2 (en) 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
JP6586016B2 (ja) * 2013-03-15 2019-10-02 ノヴォ ノルディスク アー／エス 組織因子系凝固インヒビター上の２つのエピトープに特異的に結合することが可能な抗体
CN105452298B (zh) 2013-03-15 2021-08-31 拜尔健康护理有限责任公司 改善药代动力学的具有跨pH范围差异结合的抗TFPI抗体变体
AR095502A1 (es) * 2013-03-15 2015-10-21 Bayer Healthcare Llc Anticuerpos profármaco contra el inhibidor de la vía del factor tisular
US10457743B2 (en) 2013-07-19 2019-10-29 Novo Nordisk A/S Antibodies recognizing the N-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity
US9914775B2 (en) 2013-08-21 2018-03-13 The Board Of Regents Of The University Of Texas System Methods for treating inflammatory disorders or cancer metastasis by administering antibodies to connexin 43 (Cx43) hemichannels
SG10201804945WA (en) * 2013-12-12 2018-07-30 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
PL3137502T3 (pl) * 2014-04-27 2021-03-08 Famewave Ltd. Humanizowane przeciwciała przeciwko CEACAM1
WO2016042093A1 (fr) * 2014-09-17 2016-03-24 Novo Nordisk A/S Anticorps pouvant se lier à deux épitopes sur l'inhibiteur de la voie du facteur tissulaire (1-161)
AU2015384281B2 (en) 2015-02-25 2018-11-22 Mogam Institute For Biomedical Research Novel antibody binding to TFPI and composition comprising the same
MX2018002048A (es) * 2015-08-19 2018-04-13 Pfizer Anticuerpos inhibidores de via del factor tisular y usos de los mismos.
AU2017224122B2 (en) 2016-02-26 2024-04-11 The Board Of Regents Of The University Of Texas System Connexin (Cx) 43 hemichannel-binding antibodies and uses thereof
TWI788321B (zh) * 2017-01-20 2023-01-01 美商健臻公司 骨靶向抗體
JP7094722B2 (ja) * 2018-02-28 2022-07-04 キヤノン株式会社 画像読取装置及び画像形成装置
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
JP7289913B2 (ja) * 2018-10-11 2023-06-12 ファイザー・インク Ｔｆｐｉアンタゴニストのための投薬レジメン
CN112442127A (zh) * 2019-08-29 2021-03-05 苏州康宁杰瑞生物科技有限公司 针对tfpi的单克隆抗体
CN114786717A (zh) * 2019-11-13 2022-07-22 辉瑞公司 稳定的水性抗-tfpi抗体制剂
CA3184718A1 (fr) * 2020-07-02 2022-01-06 Lei Wang Anticorps anti-fxi/fxia, fragment de liaison a l'antigene de celui-ci et utilisation pharmaceutique de celui-ci
JP7278503B2 (ja) 2020-09-24 2023-05-19 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー コンシズマブの医薬製剤およびその生産方法
WO2023143559A1 (fr) * 2022-01-30 2023-08-03 Westlake University Polypeptides de liaison à tfpi et leurs utilisations

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966852A (en) * 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
DK261490D0 (da) * 1990-10-31 1990-10-31 Novo Nordisk As New pharmaceutical compound
EP0539975A1 (fr) † 1991-10-31 1993-05-05 Teijin Limited Méthode pour le dosage immunologique de l'inhibiteur de coagulation libre associé à lipoprotéins (LACI) et trousse à cet effet
JPH06153985A (ja) * 1992-11-16 1994-06-03 Teijin Ltd モノクローナル抗体
JPH06153981A (ja) 1992-11-30 1994-06-03 Teijin Ltd Ｌａｃｉの免疫学的測定方法、それに用いるキット並びにモノクローナル抗体
US5455338A (en) * 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
US5589359A (en) 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
JPH0875736A (ja) 1994-09-06 1996-03-22 Chemo Sero Therapeut Res Inst ヒト組織因子凝固系インヒビターの定量法
US5902582A (en) * 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
JP3681206B2 (ja) 1995-12-26 2005-08-10 株式会社三菱化学ヤトロン 抗ファクターＸａ・ティシュファクターパスウェイインヒビター複合体モノクローナル抗体及びその使用
CA2288994C (fr) 1997-04-30 2011-07-05 Enzon, Inc. Polypeptides a chaine unique modifies par oxyde de polyalkylene
ES2349348T3 (es) * 2000-01-27 2010-12-30 Medimmune, Llc Anticuerpos neutralizantes de rsv de ultra alta afinidad.
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
JP2007534631A (ja) 2003-10-28 2007-11-29 ノボ　ノルディスク　アクティーゼルスカブ ラミニン−５γ２結合性ペプチド、その関連組成物およびその使用
US7585842B2 (en) 2004-04-16 2009-09-08 The Reagents Of The University Of California Human kunitz-type inhibitor with enhanced antifibrinolytic activity
US7015746B1 (en) * 2004-05-06 2006-03-21 National Semiconductor Corporation Bootstrapped bias mixer with soft start POR
CA2600907C (fr) † 2005-03-04 2016-06-28 The Board Of Trustees Of The University Of Illinois Modulateur de coagulation et de cascades fibrinolytiques
UA112050C2 (uk) 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
SI2379096T1 (sl) * 2008-12-19 2020-03-31 Baxalta GmbH Zaviralci TFPI in postopki uporabe
CN102300876A (zh) * 2008-12-22 2011-12-28 诺沃—诺迪斯克有限公司 针对组织因子途径抑制剂(tfpi)的抗体
RU2562114C2 (ru) * 2008-12-22 2015-09-10 Ново Нордиск А/С Антитела против ингибитора метаболического пути тканевого фактора
US8965454B2 (en) 2009-03-04 2015-02-24 Andrew Llc Amplifier system for cell sites and other suitable applications
CA2770762A1 (fr) 2009-08-18 2011-02-24 Baxter International Inc. Aptameres diriges contre un inhibiteur de voie de facteur tissulaire et leur utilisation comme agents therapeutiques contre des troubles du saignement
US8598327B2 (en) 2009-08-18 2013-12-03 Baxter International Inc. Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
KR101903931B1 (ko) * 2010-03-01 2018-10-02 바이엘 헬스케어 엘엘씨 조직 인자 경로 억제제 (ｔｆｐｉ)에 대한 최적화된 모노클로날 항체
US8598008B2 (en) † 2010-10-20 2013-12-03 Texas Instruments Incorporated Stacked ESD clamp with reduced variation in clamp voltage
AU2012214148A1 (en) † 2011-02-11 2013-08-29 Baxter Healthcare S.A. Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
ES2722824T3 (es) † 2011-04-01 2019-08-19 Bayer Healthcare Llc Anticuerpos monoclonales contra el inhibidor de la ruta del factor tisular (TFPI)
WO2013142153A2 (fr) † 2012-03-22 2013-09-26 Baxter International Inc. Aptamères pour l'inhibiteur de la voie du facteur tissulaire et leur utilisation comme agents thérapeutiques contre un trouble hémorragique
JP6586016B2 (ja) 2013-03-15 2019-10-02 ノヴォ ノルディスク アー／エス 組織因子系凝固インヒビター上の２つのエピトープに特異的に結合することが可能な抗体
AU2015384281B2 (en) † 2015-02-25 2018-11-22 Mogam Institute For Biomedical Research Novel antibody binding to TFPI and composition comprising the same
MX2018002048A (es) † 2015-08-19 2018-04-13 Pfizer Anticuerpos inhibidores de via del factor tisular y usos de los mismos.

Also Published As

Publication number Publication date
AU2009331570C1 (en) 2024-04-18
TWI476003B (zh) 2015-03-11
BRPI0924058A2 (pt) 2019-10-15
EP2379600B1 (fr) 2014-01-22
AU2009331570A1 (en) 2011-06-30
US20190211112A1 (en) 2019-07-11
EP2379600B2 (fr) 2020-10-14
US8361469B2 (en) 2013-01-29
US9574011B2 (en) 2017-02-21
PL2379600T5 (pl) 2021-03-08
CN102325795A (zh) 2012-01-18
TW201026330A (en) 2010-07-16
ES2458665T5 (es) 2021-06-30
JP6114326B2 (ja) 2017-04-12
PL2379600T3 (pl) 2014-07-31
IL213356A0 (en) 2011-07-31
PT2379600E (pt) 2014-04-29
CA2745317A1 (fr) 2010-07-01
US20110318356A1 (en) 2011-12-29
CA2745317C (fr) 2019-03-05
EP2746294A3 (fr) 2015-01-07
US8652471B2 (en) 2014-02-18
EP2379600A1 (fr) 2011-10-26
KR101600308B1 (ko) 2016-03-07
EP2746294A2 (fr) 2014-06-25
DK2379600T3 (da) 2014-04-28
ZA201104599B (en) 2012-03-28
CN102325795B (zh) 2015-03-25
BRPI0924058B1 (pt) 2021-08-17
ES2458665T3 (es) 2014-05-06
JP2012513377A (ja) 2012-06-14
MX2011006501A (es) 2011-07-12
US20130251721A1 (en) 2013-09-26
US20130251722A1 (en) 2013-09-26
RU2011129068A (ru) 2013-01-27
JP5714505B2 (ja) 2015-05-07
KR20110103432A (ko) 2011-09-20
JP2015178495A (ja) 2015-10-08
EP3260466A1 (fr) 2017-12-27
AU2009331570B2 (en) 2013-10-17
US20170114147A1 (en) 2017-04-27
KR101745394B1 (ko) 2017-06-09
KR20160031028A (ko) 2016-03-21
DK2379600T4 (da) 2021-01-04
WO2010072691A1 (fr) 2010-07-01
IL213356A (en) 2017-06-29
RU2562114C2 (ru) 2015-09-10

Similar Documents

Publication Publication Date Title
FR24C1008I1 (fr) Anticorps dirigés contre l'inhibiteur de la voie du facteur tissulaire
FR17C1022I2 (fr) Anticorps humains à grande affinité contre pcsk9
ES2590905T8 (es) Inhibidores de la tirosina quinasa de Bruton
BRPI0906025A2 (pt) "aparelho de refrigeração"
BRPI0906085A2 (pt) "aparelho de refrigeração"
BRPI1010909A2 (pt) "inseticida arilpirrolinas"
BRPI1013015A2 (pt) "osteosíntese com nanoprata"
ITTO20080027U1 (it) "apparato di refrigerazione domestico"
FR2908035B1 (fr) Implant interepineux
BRPI0914533A2 (pt) "métodos"
FR2932680B1 (fr) Association de tiliroside et d'un peptide
BRPI0819960A2 (pt) "biomaterial e método de preparação do mesmo"
FI20065482A0 (fi) Vuodesohva
MA30860B1 (fr) Myrtillier denomme "c97-390"
FR2929850B1 (fr) Inhibiteurs de l'enzyme tyrosinage
BRPI0906053A2 (pt) "enzima artificial"
BRPI0910484A2 (pt) esqueletos artificiais de proteína
UA18085S (uk) Шафа спеціальна хірургів для білизни та взуття
TH104914B (th) "ตู้เย็น"
TH100014B (th) "ตู้เย็น"
EE200600022A (et) Varvaste ravi-proflaktiline separaator
TH96258B (th) "แม่เหล็กติดตู้เย็น"
FR2925857B1 (fr) Implant femoral
ES1069987Y (es) "botiquin de primeros auxilios"
ATE522613T1 (de) Genetische modifikation homolaktischer thermophiler bacilli